首页> 外文期刊>Vaccine >BALB/c mice, but not C57BL/6 mice immunized with a Delta clpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: Association of protection with post-vaccination and post-challenge immune responses
【24h】

BALB/c mice, but not C57BL/6 mice immunized with a Delta clpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: Association of protection with post-vaccination and post-challenge immune responses

机译:用土拉弗朗西斯菌亚种tularensis的Delta clpB突变体免疫的BALB / c小鼠,但未免疫C57BL / 6小鼠,可抵抗野生型细菌的呼吸道攻击:疫苗接种后和攻击后免疫反应的保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

Francisella tularensis subspecies tularensis is highly virulent for humans especially when it is inhaled. Therefore, it has the potential to be used as a biothreat agent. Vaccines against F. tularensis will need to be approved in accordance with the FDA Animal Rule. This will require identification of robust correlates of protection in experimental animals and the demonstration that similar immune responses are generated in vaccinated humans. Towards this goal, we have developed an experimental live vaccine strain by deleting the gene, clpB, encoding a heat shock protein from virulent subsp. tularensis strain, SCHU S4. SCHU S4 Delta clpB administered intradermally protects BALB/c, but not C57BL/6 mice from subsequent respiratory challenge with wildtype SCHU S4. A comparison of post-vaccination and post-challenge immune responses in these two mouse strains shows an association between several antibody and cytokine responses and protection. In particular, elevated IFN gamma levels in the skin 2 days after vaccination, sero-conversion to hypothetical membrane protein ETT_778c, and to 30S ribosomal protein Si (FTT_0183c) of F. tularensis after 30 days of vaccination, and elevated levels of pulmonary IL-17 on day 7 after respiratory challenge with SCHU S4 were all associated with protection. (C) 2012 Wayne Conlan. Published by Elsevier Ltd. All rights reserved.
机译:图拉弗朗西斯菌对人类具有很高的毒性,尤其是吸入时。因此,它具有用作生物威胁剂的潜力。针对图拉菌的疫苗需要根据FDA动物法规进行批准。这将需要鉴定实验动物中强有力的保护相关性,并证明在接种疫苗的人类中会产生类似的免疫反应。为了实现这一目标,我们通过删除编码有毒亚种中热休克蛋白的基因clpB,开发了一种实验性活疫苗株。 tularensis菌株SCHU S4。皮内给药的SCHU S4 Delta clpB可以保护BALB / c,但不能保护C57BL / 6小鼠免于随后的野生型SCHU S4呼吸道攻击。在这两种小鼠品系中的疫苗接种后和攻击后免疫应答的比较显示了几种抗体与细胞因子应答和保护之间的关联。特别是疫苗接种2天后皮肤中的IFNγ水平升高,疫苗接种30天后血清转化为假单胞菌的假定膜蛋白ETT_778c和30S核糖体蛋白Si(FTT_0183c)血清,以及肺IL-水平升高用SCHU S4进行呼吸刺激后第7天的第17天都与保护相关。 (C)2012韦恩·康兰(Wayne Conlan)。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号